Wyniki wyszukiwania - Biblioteka Nauki

Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl

Ograniczanie wyników

Znaleziono wyników: 4

Liczba wyników na stronie

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych: systemic therapy

Sortuj według:

Ogranicz wyniki do:

Nasopharyngeal carcinoma – treatment possibilities in patients with primary metastatic carcinoma

100%

Kowalczyk M. , Piątek M. , Imielska-Zdunek D. , Derra A. , Zemła A. , Boratyn-Nowicka A.

OncoReview

2017

tom 7

nr 1

44-48

This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies (chemotherapy, targeted therapy, radiotherapy), and includes a case report. The applied treatment allowed for satisfactory control of the disease and much higher overall survival than expected – the patient survived for 53 months from the initial diagnosis and 41 months from being diagnosed with metastatic carcinoma.

Advanced skin melanoma – systemic treatment

100%

Kruczała M. , Ziobro M. , Grela-Wojewoda A. , Cedrych I.

2015

tom 5

nr 3

A133-138

In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcomes. This review paper presents current knowledge on systemic treatment of advanced melanoma, including treatment availability in Poland.

Abiraterone acetate – 10 clinically relevant facts

100%

Żołnierek J.

OncoReview

2021

tom 11

nr 3

80-84

Prostate cancer is one of the most frequently diagnosed cancers in men. Number of newly diagnosed cases is increasing due to several factors and the most important ones seem to be: population ageing and more sensitive diagnostic procedures. Secondary – the higher efficacy of treatment with its influence on improving patients’ overall survival and the specific mechanism of action of drugs used in systemic therapy lead to growing population of men suffering from prostate cancer in general and, specifically – patients with castration resistance. It is hormone therapy to play the key role in systemic treatment of prostate cancer with increasing significance of novel drugs focused on inhibition of molecular signal transduction mediated by androgen receptor. Abiraterone acetate is the representative of this therapeutic class. The paper describes the most clinically relevant data regarding the drug.

Biomarkers as prognostic factors in endometrial cancer

44%

Dobrzycka B. , Terlikowski S. J.

Folia Histochemica et Cytobiologica

2010

tom 48

nr 3